Millennium Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-66,180
| Closed | -$105K | – | 6777 |
|
|
2024
Q1 | $105K | Sell |
66,180
-1,196,215
| -95% | -$1.77M | ﹤0.01% | 5566 |
|
|
2023
Q4 | $1.08M | Buy |
1,262,395
+1,051,272
| +498% | +$923K | ﹤0.01% | 4092 |
|
|
2023
Q3 | $226K | Buy |
211,123
+95,519
| +83% | +$198K | ﹤0.01% | 5056 |
|
|
2023
Q2 | $299K | Sell |
115,604
-547,362
| -83% | -$1.95M | ﹤0.01% | 4886 |
|
|
2023
Q1 | $2.7M | Buy |
662,966
+204,736
| +45% | +$946K | ﹤0.01% | 3145 |
|
|
2022
Q4 | $2.3M | Buy |
458,230
+227,384
| +99% | +$1.43M | ﹤0.01% | 3460 |
|
|
2022
Q3 | $3.02M | Sell |
230,846
-210,629
| -48% | -$3.19M | ﹤0.01% | 3387 |
|
|
2022
Q2 | $5.66M | Buy |
441,475
+24,059
| +6% | +$333K | ﹤0.01% | 2672 |
|
|
2022
Q1 | $6.37M | Sell |
417,416
-116,933
| -22% | -$1.82M | ﹤0.01% | 2670 |
|
|
2021
Q4 | $9.46M | Buy |
534,349
+358,407
| +204% | +$6.88M | ﹤0.01% | 2200 |
|
|
2021
Q3 | $3.7M | Buy |
175,942
+154,441
| +718% | +$3.4M | ﹤0.01% | 3226 |
|
|
2021
Q2 | $424K | Buy |
+21,501
| New | +$503K | ﹤0.01% | 5439 |
|
|
2020
Q4 | – | Sell |
-89,803
| Closed | -$1.43M | – | 5692 |
|
|
2020
Q3 | $1.43M | Buy |
89,803
+78,100
| +667% | +$1.42M | ﹤0.01% | 2864 |
|
|
2020
Q2 | $231K | Sell |
11,703
-83,379
| -88% | -$1.59M | ﹤0.01% | 3779 |
|
|
2020
Q1 | $1.17M | Buy |
95,082
+26,647
| +39% | +$435K | ﹤0.01% | 2368 |
|
|
2019
Q4 | $1.26M | Buy |
68,435
+54,108
| +378% | +$791K | ﹤0.01% | 2885 |
|
|
2019
Q3 | $198K | Sell |
14,327
-34,689
| -71% | -$521K | ﹤0.01% | 3796 |
|
|
2019
Q2 | $718K | Buy |
+49,016
| New | +$717K | ﹤0.01% | 3010 |
|
Millennium Management's NGM Position: Q2 2024 in Review
Millennium Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 66,180 shares — an estimated $105K sold.
Millennium Management first reported a position in NGM in Q2 2019 and held it in 18 quarters. The position peaked at $9.46M in Q4 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Millennium Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Millennium Management sold 66,180 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $105K.
- Millennium Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
- Millennium Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $9.46M in Q4 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.